As industrial drone adoption grows, startups are finding bigger opportunities in infrastructure, inspections and field operations.
Updated
May 25, 2026 3:21 PM

An oil pump on a field. PHOTO: UNSPLASH
As drone adoption grows across industrial sectors, more startups are moving beyond hardware sales and into service-based business models. Instead of simply selling drones, companies are increasingly trying to build recurring revenue through inspection, mapping and infrastructure-monitoring services. That shift is shaping ZenaTech’s latest expansion strategy.
ZenaTech is a Vancouver-based startup that develops AI drone and Drone as a Service (DaaS) technologies. The company has signed an offer to acquire an Alberta-based land surveying and geomatics business operating across Western Canada. If completed, the deal would mark ZenaTech’s first land surveying acquisition in Canada and its first major push into the oil and gas sector.
The move gives the startup something more valuable than just another acquisition target. It provides direct access to an industry where drones are already becoming part of everyday operations.
The Alberta surveying company works with oil and gas producers across Alberta, Eastern British Columbia and Saskatchewan. Its services include land surveying, geomatics, mapping and environmental support for infrastructure and energy development projects.
According to ZenaTech, drones are already used in roughly 80 percent of the target company’s existing projects. That matters because it reduces the operational gap between traditional surveying work and AI-powered automation.
Rather than introducing drones into a completely manual workflow, ZenaTech is entering a business where drone-based data collection is already established. The startup says it plans to build on that foundation by integrating more AI-powered capabilities across surveying, mapping, inspections and infrastructure monitoring.
Shaun Passley, Ph.D., CEO of ZenaTech, said: "This proposed acquisition represents an important strategic expansion of our Drone as a Service business into Canada’s oil and gas sector, one of the most significant energy markets in North America. This company brings an established commercial customer base, strong regional expertise, and extensive experience supporting surveying and geomatics projects including for some large producers. We believe there is a significant opportunity to further enhance these services through AI-powered drone technology for surveying, mapping, inspections, and infrastructure monitoring applications, enabling us to establish a core expertise that we can bring to this fast-growing global industry."
The timing is also significant. ZenaTech pointed to estimates showing the global oil and gas drone inspection services market is currently valued at around US$ 2.3 billion and projected to grow at a compound annual growth rate of roughly 28.5 percent.
Much of that growth is being driven by energy companies looking for faster ways to inspect infrastructure, monitor remote sites and reduce manual field operations.
ZenaTech’s broader strategy centers around building a global DaaS network through acquisitions. Instead of creating local operations from scratch, the startup is acquiring existing service businesses with established customers and then layering drone automation and AI systems into those operations.
The company says its DaaS platform offers businesses and government clients subscription-based or on-demand drone services across areas such as inspections, surveying, maintenance, inventory management and precision agriculture.
The larger opportunity for startups in this space may not be drone manufacturing alone. Increasingly, the focus is shifting toward startups that can build scalable drone service networks and integrate them into industries that already rely on large-scale field operations. Oil and gas appear to be one of the next major targets for that expansion.
Keep Reading
A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
May 1, 2026 2:25 PM

Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.